Literature DB >> 15336434

[Macrophage activation syndrome, hemophagocytic syndrome].

A Pradalier1, F Teillet, J-L Molitor, J-C Drappier.   

Abstract

Macrophage activation syndrome MAS describes the clinical, biological and histological symptoms related to a probably T lymphocytes/NK cell driven stimulation of macrophages with the consequence of a hemophagocytosis involving numerous organs, preferentially bone marrow, explaining the other term of "hemophagocytic syndrome". Clinical symptoms include cytopenia, multiple organ dysfunction, fever unresponsive to antibiotics, fatigue and rash. Infections (bacteria, virus or parasites), lymphoproliferative disorders, cancers, systemic diseases are the most prevalent triggers or etiologies of M.A.S. Evidence of haemaphagocytosis is obtained in the majority of cases with bone marrow specimens. In some cases haemophagocytosis can spare the bone marrow with involvement confined to other tissues such as liver and spleen. Very high levels of ferritine seem to correlate well with the presence of haemophagocytosis and is a possible marker for an early diagnosis. Early treatment initiation is mandatory. Corticosteroids, cytostatic drugs such as etoposide, cyclosporine A, plasmapherese, intravenous immunoglobulins and anti TNFalpha are proposed but no randomized trials were published.

Entities:  

Mesh:

Year:  2004        PMID: 15336434     DOI: 10.1016/j.patbio.2003.12.001

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  3 in total

1.  Hemophagocytic lymphohistiocytosis: epidemiological, clinical and biological profile

Authors:  Hanane Zahir; Jihane Belkhir; Hanane Mouhib; Mustapha Ait Ameur; Mohammed Chakour
Journal:  Turk J Med Sci       Date:  2019-10-24       Impact factor: 0.973

2.  Macrophage activation syndrome during Crohn´s disease: a case report.

Authors:  Oussama Kharmach; Nawal Lagdali; Imane Benelbarhdadi; Mohammed Borahma; Fatima-Zohra Ajana
Journal:  Pan Afr Med J       Date:  2022-06-06

3.  [Pathogenesis and morphology of hemophagocytic syndrome in the spleen].

Authors:  S Gattenlöhner; H K Müller-Hermelink
Journal:  Pathologe       Date:  2008-03       Impact factor: 0.973

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.